Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback